It follows our live coverage of ASCO 2020 day 1 and day 2, during which we’ve already featured Amgen’s Kyprolis, AstraZeneca’s Tagrisso, rare cancers and genomics, BCMA therapy, COVID-19’s impact on cancer patients and much more.
View all the live coverage of the virtual ASCO 2020, and day three live blog is below (please allow the blog a few moments to load):
Johnson & Johnson’s Janssen unit also has some interesting data
from a bispecific antibody aimed at lung cancers with a mutation that
renders approved targeted drugs useless.
Amivantamab was created in collaboration with its development partner Genmab and the latest data from Janssen came from a small study in non-small cell lung cancer with EGFR exon20 insertion mutations.
Data came from the study of 50 patients, of whom 39 were evaluable at data cut-off in October.
This showed an overall response rate of 36%, and 41% in patients who had already received platinum-based chemotherapy.
The clinical benefit rate was 67% overall and 72% for patients who had already received platinum chemo.
In the 14 responders, median duration of response was 10 months, with ongoing responses in nine patients at data cutoff.
Median progression-free survival was 8.3 months for response evaluable patients, and 8,6 months in those previously treated with platinum chemo.
In a briefing ahead of ASCO J&J pointed out that PFS is typically around 3.7 months in this patient group.
As there are no approved targeted therapies for this kind of lung cancer, the FDA has granted Breakthrough Therapy status to amivantamab in this form of lung cancer earlier this year.
Amivantamab was created in collaboration with its development partner Genmab and the latest data from Janssen came from a small study in non-small cell lung cancer with EGFR exon20 insertion mutations.
Data came from the study of 50 patients, of whom 39 were evaluable at data cut-off in October.
This showed an overall response rate of 36%, and 41% in patients who had already received platinum-based chemotherapy.
The clinical benefit rate was 67% overall and 72% for patients who had already received platinum chemo.
In the 14 responders, median duration of response was 10 months, with ongoing responses in nine patients at data cutoff.
Median progression-free survival was 8.3 months for response evaluable patients, and 8,6 months in those previously treated with platinum chemo.
In a briefing ahead of ASCO J&J pointed out that PFS is typically around 3.7 months in this patient group.
As there are no approved targeted therapies for this kind of lung cancer, the FDA has granted Breakthrough Therapy status to amivantamab in this form of lung cancer earlier this year.
Seeing a lot of positive comments about the Lost in the Woods?
presentation on seeking novel therapies from the patient’s perspective
from Dr Mark Lewis, director of gastrointestinal oncology at
Intermountain Healthcare.
His take home points:
– Don’t underestimate tech-savvy, self-advocating patients
– Physicians – teach patients to use clinicaltrials.gov
– Driver mutations are breaking down traditional histopathologic boundaries
– The past was ‘shotgun’ toxicity, the future is ‘sniper’ aim
– Patients are our partners in progress
His take home points:
– Don’t underestimate tech-savvy, self-advocating patients
– Physicians – teach patients to use clinicaltrials.gov
– Driver mutations are breaking down traditional histopathologic boundaries
– The past was ‘shotgun’ toxicity, the future is ‘sniper’ aim
– Patients are our partners in progress
ASCO is saving its analysis of the ADAURA trial, the latest lung
cancer data from AstraZeneca’s lung cancer drug Tagrisso (osimertinib)
for its big plenary session in the afternoon.
But Benjamin Levy, clinical director of oncology at the Johns Hopkins Sidney Kimmel Cancer Center took us through the latest data from Bristol-Myers Squibb’s immunotherapy combination in first line lung cancer.
In the past few weeks BMS scored two FDA wins with the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) in first line lung cancer.
An approval in first-line non-small cell lung cancer offered patients with the PD-L1 biomarker present in at least 1% of tumour cells the option of a chemotherapy-free regimen.
The other approval gave the option of Opdivo and Yervoy plus doublet chemotherapy regardless of the presence of PD-L1.
Levy’s conclusion is that these do offer two new options, although he cited concerns about the toxicity profile of the combination without chemotherapy, which caused 12% of patients to quit.
He wants to see five year data to select the best regimen in what is becoming a quite crowded field, with Merck & Co’s Keytruda (pembrolizumab) still the main contender.
He concluded with a lesson learned from AstraZeneca’s Imfinzi (durvalumab), which failed in the MYSTIC trial in first line lung cancer in 2017,.
Levy noted a 2018 exploratory analysis of the data showed “competitive outcomes” based on the plasma tumour mutation burden biomarker.
According to Levy this shows the “need to move beyond PD-L1 and find better biomarkers.”
But Benjamin Levy, clinical director of oncology at the Johns Hopkins Sidney Kimmel Cancer Center took us through the latest data from Bristol-Myers Squibb’s immunotherapy combination in first line lung cancer.
In the past few weeks BMS scored two FDA wins with the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) in first line lung cancer.
An approval in first-line non-small cell lung cancer offered patients with the PD-L1 biomarker present in at least 1% of tumour cells the option of a chemotherapy-free regimen.
The other approval gave the option of Opdivo and Yervoy plus doublet chemotherapy regardless of the presence of PD-L1.
Levy’s conclusion is that these do offer two new options, although he cited concerns about the toxicity profile of the combination without chemotherapy, which caused 12% of patients to quit.
He wants to see five year data to select the best regimen in what is becoming a quite crowded field, with Merck & Co’s Keytruda (pembrolizumab) still the main contender.
He concluded with a lesson learned from AstraZeneca’s Imfinzi (durvalumab), which failed in the MYSTIC trial in first line lung cancer in 2017,.
Levy noted a 2018 exploratory analysis of the data showed “competitive outcomes” based on the plasma tumour mutation burden biomarker.
According to Levy this shows the “need to move beyond PD-L1 and find better biomarkers.”
[MORE]
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.